Aumolertinib Combined with Chemotherapy Enhances Progression-Free Survival in NSCLC Patients Harboring EGFR and Tumor Suppressor Gene Alterations: Findings from the ACROSS 2 Phase III Trial
In a pivotal advancement for the treatment of advanced non-small cell lung cancer (NSCLC), new data from the ACROSS 2 ...
